WHOOP Announces Global Partnership with Cristiano Ronaldo
13.5.2024 13:00:00 EEST | Business Wire | Press release
WHOOP, the human performance company, today announced Cristiano Ronaldo, the legendary football icon, as an official global ambassador and investor. This represents one of Ronaldo's most significant investments to date. Ronaldo joins the company’s growing roster of global ambassador investors, including Patrick Mahomes, Michael Phelps, Eli Manning, Rory McIlroy, and more. Announced earlier this morning on Instagram Live, this partnership signifies the company’s global growth trajectory and commitment to revolutionizing the world of human performance.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240513817139/en/
WHOOP announces global partnership with Cristiano Ronaldo. (Photo: Business Wire)
The partnership between WHOOP and Ronaldo is an obvious one. Ronaldo’s success has been built on an obsession to perform at the highest levels. First to training, last to leave - former teammates speak of his dedication to self improvement having been the driving force behind his success. Cristiano is still performing at a very high level. He was the highest scorer in the World in 2023, is currently the top scorer in the Saudi Pro League, and is preparing for the Euros this summer. Ronaldo and WHOOP will partner on product development and leverage data-driven insights to help deliver the best health and fitness coaching for athletes and humanity broadly.
“Cristiano has been a WHOOP member for a number of years, and we’re proud to strengthen our relationship further through this partnership,” said Will Ahmed, WHOOP Founder and CEO. “Cristiano’s relentless pursuit of improvement and perfection mirrors our mission. We are looking forward to collaborating with him to share unprecedented insights into his training and recovery methods. Together, we'll unveil exciting product collaborations to enhance the WHOOP experience for our members.”
Cristiano Ronaldo, one of the greatest players in the history of football, has achieved unparalleled success across various prestigious football leagues worldwide, including the Premier League (Manchester United 2003-09; 2021-23), LaLiga (Real Madrid 2009-18), Serie A (Juventus 2018-22), and most recently, the Saudi Pro League (Al Nassr 2022-Present). As the leading scorer in the history of top-level association football globally, with 891 goals and counting, Ronaldo has won seven league titles and five UEFA Champions Leagues and is a five-time winner of the Ballon d'Or.
Ronaldo has also represented his home country of Portugal in international competition with the senior team since 2003, appearing in 206 matches to date and scoring 128 goals. His contributions have led Portugal to victory in the UEFA European Championship in 2016 and the UEFA Nations League title in 2019.
“WHOOP has had a transformative impact on my life both on and off the pitch, and I’m honored to join the team as an investor,” said Cristiano Ronaldo. “I wear WHOOP while training, sleeping, and recovering. It’s been one of the most important tools helping me elevate my game and monitor my health. I look forward to working with WHOOP to continue to raise the bar on WHOOP features and coaching.”
The partnership and investment from Ronaldo coincide with the announcement of WHOOP expanding its availability to Gulf Cooperation Council regions - Saudi Arabia, Qatar, Kuwait, Bahrain - in addition to Hong Kong, Israel, Korea, and Taiwan. Furthermore, by the time of the announcement, WHOOP will have extended its shipping services to India, Mexico, and Brazil, ensuring a seamless experience for members across these markets.
For more information on WHOOP x Ronaldo, please visit www.whoop.com/cr7.
ABOUT WHOOP
WHOOP, the human performance company, offers a wearable health and fitness coach to help people achieve their goals. The WHOOP membership provides best-in-class wearable technology, actionable feedback, and recommendations across recovery, sleep, training, and health. WHOOP serves professional athletes, Fortune 500 CEOs, executives, fitness enthusiasts, military personnel, frontline workers, and anyone looking to improve their performance. WHOOP Unite is a comprehensive solution dedicated to supporting organizations across a wide range of industries with coaching, organizational insights, and health programs. Studies show WHOOP can positively change behavior, increase sleep, and improve physiological biomarkers. Founded in 2012, WHOOP is based in Boston and has raised more than $400 million in venture capital. The latest round of financing made WHOOP the world's most valuable standalone wearables company. Visit WHOOP.com for more information and connect with WHOOP on Instagram, Twitter, Facebook, LinkedIn, and YouTube.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240513817139/en/
Contact information
PRESS CONTACT:
Will McClaran
Jack Taylor PR
whoop@jacktaylorpr.com
GCC PRESS CONTACT:
Aaron Illathu
Jack Taylor PR
aaron@jacktaylorpr.com
+971 585 575 2884
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mosaic Clinical Technologies Announces FDA Breakthrough Device Designation for Cognita’s Generative AI Model for Radiology5.3.2026 09:00:00 EET | Press release
Mosaic Clinical Technologies™, a wholly-owned subsidiary of Radiology Partners, is pleased to announce that Cognita™, its AI business unit developing generative vision-language models (VLMs) for radiology, has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for Cognita Chest X-Ray (CXR)™1 across multiple critical indications. Cognita CXR is an industry-first generative vision-language model designed to assist radiologists in the interpretation of chest X-rays and is the first radiology generative AI model, and one of very few radiology AI solutions, to be granted this designation2. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304633206/en/ Cognita™ operates as the AI business unit of Mosaic Clinical Technologies™, a wholly owned subsidiary of Radiology Partners, the largest radiology practice in the U.S, with more than 4,000 radiologists in its network. Cognita CXR1 applies a proprietary
SOLUM and Simbe Expand European Collaboration to Advance Intelligent Store Operations5.3.2026 09:00:00 EET | Press release
SOLUM (KOSPI: 248070) and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. The collaboration was highlighted at EuroShop, where Simbe’s Store Intelligence™ platform was demonstrated live at the SOLUM booth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304620371/en/ SOLUM and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. (Image: SOLUM) Simbe recently introduced Tally 4.0, the next generation of their autonomous shelf-scanning robot, reflecting the company’s continued evolution in retail shelf digitization, incorporating extended runtime, enhanced edge computing, and advanced vision capabilities. Designed to deliver deeper shelf coverag
Cielo Advances Resilient Remote Connectivity for Its Nationwide Payment Terminal Fleet With Thales5.3.2026 09:00:00 EET | Press release
For Cielo, connectivity is mission critical. When payment terminals lose network access, transactions stop. To strengthen operational resilience and enhance merchant experience, Cielo is modernizing its connectivity architecture across its terminal fleet. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304089321/en/ Cielo advances resilient remote connectivity for its nationwide payment terminal fleet with Thales. Using Thales’s eSIM technology as part of this strategy, Cielo can remotely switch mobile network operators over the air in just a few seconds, without sending a technician and with minimal disruption to merchants’ activity. For merchants, the experience is seamless: if a network becomes unstable, the payment terminal can automatically reconnect to another available network, often without the merchant even noticing. This deployment represents one of the first large-scale implementations of the SGP.32 eSIM specifi
GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe.5.3.2026 09:00:00 EET | Press release
GAIA, the pioneer in evidence-based digital therapeutics and Daiichi Sankyo Europe, today announced an exclusive strategic partnership to commercialize lipodia upon regulatory approval1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224658973/en/ Dr. Mario Weiss, Founder & CEO of GAIA AG This digital therapeutic is designed to support adults living with hypercholesterolemia. The comprehensive collaboration brings together GAIA’s long-standing expertise in developing clinically validated non-pharmacological interventions with Daiichi Sankyo’s highly scientific experience in cardiovascular risk management and health. Together, the partners - both members of the German Association of Research-Based Pharmaceutical Companies (vfa) - aim to address a persistent gap in chronic care: leveraging digital technologies to make a difference in patients’ lives by supporting sustainable, long-term behaviour change. Expanding Cardiovasc
Galderma Delivers Record 2025 Results With Net Sales of 5.207 Billion USD, up 17.7% at Constant Currency 1 , and Core EBITDA 2 of 1.211 billion USD, Growing 18.9% at Constant Currency5.3.2026 08:00:00 EET | Press release
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year 2025. Record net sales of 5,207 million USD, surpassing 5 billion USD in a year for the first time and representing 17.7% year-on-year growth on a constant currency1 basis, primarily driven by volume. Broad-based net sales growth, growing double-digits in both International markets and the U.S. Outperforming the market in each product category, with strong net sales growth in Injectable Aesthetics (11.5%), Dermatological Skincare (9.3%) and Therapeutic Dermatology (50.2%), all year-on-year at constant currency. Strong launch momentum across future growth drivers, including Nemluvio® (nemolizumab) delivering 452 million USD in net sales; Relfydess™ (RelabotulinumtoxinA) outperforming expectations in 17 International markets; Sculptra® gaining significant market share in its first year in China; and continued new product launches across Galderma’s full portfoli
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom